What question did this study set out to answer?

The aim is to compare the efficacy and safety of SGLT-2 inhibitors versus other oral dual therapies combined with metformin in treating type 2 diabetes.

February 14, 2026Endocrinology Diabetes & MetabolismOpen Access

Comparing SGLT2i and Other Oral Antidiabetic Drugs as Dual Therapy Add‐On to Metformin in Type 2 Diabetes: A Systematic Review and Meta‐Analysis

View Full Paper

Ask AI

Bookmark

Authors

YMYuhang MaShanghai Jiao Tong University YLYi Lin XDXiaoying Ding

Discussion

Member takes

Implication

A systematic review compares efficacy and safety of SGLT2 inhibitors in type 2 diabetes, suggesting potential benefits.

Key Points

The aim is to compare the efficacy and safety of SGLT-2 inhibitors versus other oral dual therapies combined with metformin in treating type 2 diabetes.
Updated systematic literature review using databases like MEDLINE and Embase.
Identified randomised controlled trials related to SGLT-2i and metformin.
Assessed studies for eligibility and quality using the Cochrane Risk of Bias tool.
Conducted meta-analysis with random-effects pairwise models.
SGLT-2i plus metformin showed similar HbA1c changes compared to other metformin ODTs at Weeks 24 and 52.
Patients on SGLT-2i plus metformin had a lower risk of hypoglycaemia (RR: 0.27).
Participants experienced a greater weight reduction (MD: –2.59) on SGLT-2i plus metformin.
There was an increased risk of genital infection (RR: 5.08) compared to other ODTs.
Other safety outcomes, such as urinary tract infections, were similar between groups.

Cite This Study

Ma et al. (2026) studied this question.

synapsesocial.com/papers/699010ce2ccff479cfe56ff7 https://doi.org/10.1002/edm2.70176

View Full Paper

Ask AI

Bookmark

Comparing SGLT2i and Other Oral Antidiabetic Drugs as Dual Therapy Add‐On to Metformin in Type 2 Diabetes: A Systematic Review and Meta‐Analysis

Discussion

Member takes

Implication

Key Points

Cite This Study

Comparing SGLT2i and Other Oral Antidiabetic Drugs as Dual Therapy Add‐On to Metformin in Type 2 Diabetes: A Systematic Review and Meta‐Analysis

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider